Listing a study does not mean it has been evaluated by the U. Giving hydroxychloroquine together with temozolomide and radiation therapy may kill more tumor cells. RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine hypercalcemia Lariago chloroquine phosphate 250 mg Hydroxychloroquine HCQ, sold under the brand name Plaquenil among others, is a medication used for the prevention and treatment of certain types of malaria. Specifically it is used for chloroquine-sensitive malaria. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth. Plaquenil Hydroxychloroquine belongs to a group of medications known as anti-inflammatories and antimalarials. It is used alone or in combination with other anti-arthritic medications to treat rheumatoid arthritis. It helps to reduce pain, stiffness, and swelling in joints. Commencement of protocol therapy began as soon as medically appropriate, but, no later than 3 mo after craniotomy. All subjects received conventional external beam RT as utilized by the Radiation Therapy Oncology Group. This consisted of 60 Gy in 30 fractions delivered with megavoltage machines. Cohorts of 3-6 patients receive escalating doses of hydroxychloroquine until the maximum tolerated dose (MTD) is determined. Complete 10 week cycle -Initiation Phase Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. cohorts of three pts: dose levels: 200, 400, 800mg. Other: pharmacological study (PK) pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1 Radiation (RT)Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. Complete 10 week cycle -Initiation Phase Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Other: pharmacological study (PK) Pts will continue on treatment until tumor progression. PURPOSE: This phase I/II trial is studying the side effects and best dose of hydroxychloroquine when given together with radiation therapy and temozolomide and to see how well they work in treating patients with newly diagnosed glioblastoma multiforme. Complete 10 week cycle -Initiation Phase Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. cohorts of three pts: dose levels: 200, 400, 800mg. Other: pharmacological study (PK) pts continue on treatment until tumor progression. Plaquenil radiation therapy Hydroxychloroquine, Radiation, and Temozolomide Treating., Plaquenil - Uses, Side Effects, Interactions - Plaquenil liver side effectsIs chloroquine toxic to cellsWill plaquenil help cancer Skin Reactions from Radiation Treatments Skin reactions are a common side effect of radiation treatments. They are caused when repeated doses of radiation pass through the skin. Skin reactions occur within “treatment fields.” Treatment fields are the parts of the body that are treated with radiation. Skin Skin Reactions from Radiation Treatments. A phase I/II trial of. - PubMed Central PMC. Plaquenil Hydroxychloroquine - Side Effects, Dosage.. Low-dose therapy is less likely to harm the retina, but if it does, early treatment may reverse the damage. Most adverse eye reactions occur in patients who take more than 400 mg of Plaquenil daily. The initial dosage range is 400 to 600 mg/day, but once the patient has a therapeutic response, the dose can be reduced. This phase I / II trial studies the side effects and best dose of hydroxychloroquine and how well CPI-613 and hydroxychloroquine work in treating patients with high risk myelodysplastic syndrome that has come back after hypomethylating therapy. CPI-613 is thought to kill cancer cells by turning off their mitochondria. Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. S. Federal Government.